{"id":8319,"date":"2026-11-05T08:00:00","date_gmt":"2026-11-05T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/"},"modified":"2026-11-05T08:00:00","modified_gmt":"2026-11-05T07:00:00","slug":"nanexa-publicerar-delarsrapport-for-juli-september-2026","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r juli-september 2026"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Strategiskt viktigt tredje kvartal f\u00f6r Nanexa med Novo-avtal och vetenskapliga och operativa framsteg<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>V\u00e4sentliga h\u00e4ndelser under tredje kvartalet 2026<\/p>\n<ul>\n<li>Nanexa meddelade den 24 september att ett globalt licens-och samarbetsavtal ing\u00e5tts med Novo avseende l\u00e5ngverkande injicerbara l\u00e4kemedel. Avtalet \u00e4r v\u00e4rt 1,165 miljarder euro varav 20 miljoner euro i en initial betalning f\u00f6ljd av 595 miljoner euro i utvecklings- och regulatoriska milstolpebetalningar. Resterande milstolpebetalningar \u00e4r f\u00f6rs\u00e4ljningsrelaterade. D\u00e4rut\u00f6ver har Nanexa r\u00e4tt till en l\u00e5g ensiffrig royalty p\u00e5 global nettof\u00f6rs\u00e4ljning av produkter som utvecklas inom ramen f\u00f6r avtalet. Avtalet ger Novo en global exklusiv licens till Nanexas egenutvecklade drug delivery-plattform PharmaShell\u00ae, baserad p\u00e5 atomic layer deposition (ALD), f\u00f6r vissa terapeutiska peptidl\u00e4kemedel inom indikationer som inkluderar obesitas, typ 2-diabetes och andra kardiometabola sjukdomar.<\/li>\n<li>Nanexa meddelade den 22 september att ett gemensamt utvecklingsavtal ing\u00e5tts med Forge Nano f\u00f6r att utveckla tillverkning av ALD-belagda, l\u00e5ngverkande injicerbara l\u00e4kemedel med PharmaShell\u00ae. Samarbetet syftar till att utveckla storskalig, GMP-kompatibel ALD-tillverkningsutrustning som st\u00f6djer Nanexas breda portf\u00f6lj av egna och partnerdrivna PharmaShell\u00ae-program.<\/li>\n<\/ul>\n<p>Finansiell \u00f6versikt<\/p>\n<p>1 juli &#8211; 30 september 2026<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 227 865 (477) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: 157\u00a0332 (-11 983) kSEK<\/li>\n<li>Periodens resultat uppgick till: 157 384 (-12 538) kSEK<\/li>\n<li>Resultat per aktie f\u00f6re utsp\u00e4dning uppgick till: 0,82 (-0,08) SEK<\/li>\n<li>Resultat per aktie efter utsp\u00e4dning uppgick till: 0,80 (-0,07) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -8 524 (-15 483) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 44 033 (24 779) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida: <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" rel=\"noopener\" target=\"_blank\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p>Rapportkommentar 5 november kl. 10:30<\/p>\n<p>En lives\u00e4nd kommentar med vd David Westberg och styrelseordf\u00f6rande G\u00f6ran Ando h\u00e5lls den 5 november kl. 10:30 via Infront Direkt Studios och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p>Rapportkommentaren kommer att finnas tillg\u00e4nglig via <a href=\"https:\/\/eur01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fyoutube.com%2Flive%2FxNiDsitmF04&amp;data=05|02|maria.medeen%40nanexa.se|65882e0448c342458fd508df398f5232|cf2057b571ae407dac1e06fc7f9e6904|0|0|639292959898935076|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=Be6n18pr%2BVBrSZpXkeyZuh9gArQ1gotRCgYEQ4nvEgg%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">denna l\u00e4nk<\/a><\/p>\n<p>Rapportkommentaren kommer \u00e4ven att l\u00e4ggas upp p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 vd, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>Email:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Tapper Partners AB.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa introducerar kontroll, precision och m\u00e5ngsidighet till l\u00e4kemedelsformuleringar med hj\u00e4lp av ALD-teknik (Atomic Layer Deposition). F\u00f6retagets patenterade PharmaShell\u00ae-plattform \u00e4r ett unikt drug delivery-system som m\u00f6jligg\u00f6r h\u00f6g drug load vilket ger l\u00e5g injektionsvolym och skapar en ny generation formuleringar, s\u00e5 kallade \u201dsuper generics\u201d som ger st\u00f6rre bekv\u00e4mlighet och minskar kostnaderna vid behandling av allehanda sjukdomstillst\u00e5nd som metabola sjukdomar, t ex typ 2-diabetes och obesitas, hematologi\/onkologi, hj\u00e4rt-k\u00e4rlsjukdomar, psykiatri och m\u00e5nga andra.<br \/>Nanexa utvecklar egna l\u00e4kemedelsprodukter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland det senaste licens- och optionsavtalet med Moderna.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2026-11-05 08:00 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/61eb1648-8914-4727-ae5e-29fa70281f8a\/nanexa-ab-delarsrapport-juli-sept-2026.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa AB Del\u00e5rsrapport Juli Sept 2026<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Strategiskt viktigt tredje kvartal f\u00f6r Nanexa med Novo-avtal och vetenskapliga och operativa framsteg<\/p>\n","protected":false},"template":"","class_list":["post-8319","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn-arc-event_sv","mfn-news-tag-mfn-arc-event-report_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q3_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r juli-september 2026 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r juli-september 2026 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Strategiskt viktigt tredje kvartal f\u00f6r Nanexa med Novo-avtal och vetenskapliga och operativa framsteg\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-juli-september-2026\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-juli-september-2026\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r juli-september 2026 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2026-11-05T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-juli-september-2026\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-juli-september-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-juli-september-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r juli-september 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r juli-september 2026 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r juli-september 2026 - Nanexa AB","og_description":"Strategiskt viktigt tredje kvartal f\u00f6r Nanexa med Novo-avtal och vetenskapliga och operativa framsteg","og_url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/","url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r juli-september 2026 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2026-11-05T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-juli-september-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r juli-september 2026"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/8319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=8319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}